Skip to main content
Erschienen in: Digestive Diseases and Sciences 12/2006

01.12.2006 | Original Paper

Correlation of GLUT-1 Overexpression, Tumor Size, and Depth of Invasion with 18F-2-fluoro-2-deoxy-d-glucose Uptake by Positron Emission Tomography in Colorectal Cancer

verfasst von: Jinyu Gu, Hirofumi Yamamoto, Hiroki Fukunaga, Katsuki Danno, Ichiro Takemasa, Masataka Ikeda, Mitsuaki Tatsumi, Mitsugu Sekimoto, Jun Hatazawa, Tsunehiko Nishimura, Morito Monden

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2006

Einloggen, um Zugang zu erhalten

Abstract

We investigated the wide variability of 18F-2-fluoro-2-deoxy-d-glucose (FDG) uptake, semiquantified as standardized uptake value (SUV), in positron emission tomography (PET) scanning, in 20 patients with colorectal cancer (CRC), including 1 with synchronous hepatic metastasis. The sensitivity of PET in CRC diagnosis was 100%, with a mean SUV of 8.0 (3.1–11.9). Tumor size and depth of invasion were associated with higher SUVs (P=.0004, .042, respectively). Strong glucose transporter-1 (GLUT-1) expression had significantly positive correlation with the SUV (r=.619, P=.003). GLUT-1 expression revealed positive staining in 17 (85%) of the 20 primary lesions. The central part of the tumor, thought to be relatively hypoxic, had stronger GLUT-1 expression and a higher SUV than the periphery, in both the primary tumor and hepatic metastatic foci. Our data suggest that the SUVs of FDG uptake in PET may be a noninvasive biomarker for advanced CRC, indicative of a large hypoxic tumor with deep invasion.
Literatur
1.
Zurück zum Zitat Truant S, Huglo D, Hebbar M, Ernst O, Steinling M, Pruvot FR (2005) Prospective evaluation of the impact of [18F]fluoro-2-deoxy-d-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 92:362–369CrossRefPubMed Truant S, Huglo D, Hebbar M, Ernst O, Steinling M, Pruvot FR (2005) Prospective evaluation of the impact of [18F]fluoro-2-deoxy-d-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 92:362–369CrossRefPubMed
2.
Zurück zum Zitat Delbeke D, Martin WH (2004) PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med 34:209–223CrossRefPubMed Delbeke D, Martin WH (2004) PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med 34:209–223CrossRefPubMed
3.
Zurück zum Zitat Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Ruhl A, Irngartinger G, Stremmel W, Rudi J (2004) Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med 45: 1480–1487PubMed Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Ruhl A, Irngartinger G, Stremmel W, Rudi J (2004) Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med 45: 1480–1487PubMed
4.
Zurück zum Zitat Wong CY, Salem R, Qing F, Wong KT, Barker D, Gates V, Lewandowski R, Hill EA, Dworkin HJ, Nagle C (2004) Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 45:1892–1897PubMed Wong CY, Salem R, Qing F, Wong KT, Barker D, Gates V, Lewandowski R, Hill EA, Dworkin HJ, Nagle C (2004) Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 45:1892–1897PubMed
5.
Zurück zum Zitat Rohren EM, Paulson EK, Hagge RH, Wong TZ, Killius J, Clavien PA, Nelson RC (2002) The role of F-18-FDG PET in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin Nucl Med 27:550–555CrossRefPubMed Rohren EM, Paulson EK, Hagge RH, Wong TZ, Killius J, Clavien PA, Nelson RC (2002) The role of F-18-FDG PET in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin Nucl Med 27:550–555CrossRefPubMed
6.
Zurück zum Zitat Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231:305–332PubMed Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231:305–332PubMed
7.
Zurück zum Zitat Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F (2004) Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 109:926–932CrossRefPubMed Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F (2004) Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 109:926–932CrossRefPubMed
8.
Zurück zum Zitat Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC (2004) Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 25:11–17CrossRefPubMed Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC (2004) Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 25:11–17CrossRefPubMed
9.
Zurück zum Zitat Bos R, Van Der Hoeven JJ, Van Der Wall E, Van Der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CF (2002) Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20:379–387CrossRefPubMed Bos R, Van Der Hoeven JJ, Van Der Wall E, Van Der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CF (2002) Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20:379–387CrossRefPubMed
10.
Zurück zum Zitat Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA (2004) Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245–2252CrossRefPubMed Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA (2004) Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245–2252CrossRefPubMed
11.
Zurück zum Zitat Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC, Humm JL (2005) Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 62:545–553CrossRefPubMed Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC, Humm JL (2005) Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 62:545–553CrossRefPubMed
12.
Zurück zum Zitat Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, Lin WJ, Chen JT, Chen WJ, Lai CR, Hsueh S (2004) 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 45:22–29PubMed Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, Lin WJ, Chen JT, Chen WJ, Lai CR, Hsueh S (2004) 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 45:22–29PubMed
13.
Zurück zum Zitat Kato H, Takita J, Miyazaki T, Nakajima M, Fukai Y, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Kuwano H, Oriuchi N, Endo K (2003) Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res 23:3263–3272PubMed Kato H, Takita J, Miyazaki T, Nakajima M, Fukai Y, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Kuwano H, Oriuchi N, Endo K (2003) Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res 23:3263–3272PubMed
14.
Zurück zum Zitat Koga H, Matsuo Y, Sasaki M, Nakagawa M, Kaneko K, Hayashi K, Kuwabara Y, Honda H (2003) Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma. Ann Nucl Med 17:327–331PubMedCrossRef Koga H, Matsuo Y, Sasaki M, Nakagawa M, Kaneko K, Hayashi K, Kuwabara Y, Honda H (2003) Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma. Ann Nucl Med 17:327–331PubMedCrossRef
15.
Zurück zum Zitat Paul AK, Tatsumi M, Higuchi I, Fukunaga H, Yasuda T, Nishimura T (2003) Gamma camera coincidence imaging with [18F]fluorodeoxyglucose in the pretreatment evaluation of patients with oesophageal cancer. Nucl Med Commun 24:963–970CrossRefPubMed Paul AK, Tatsumi M, Higuchi I, Fukunaga H, Yasuda T, Nishimura T (2003) Gamma camera coincidence imaging with [18F]fluorodeoxyglucose in the pretreatment evaluation of patients with oesophageal cancer. Nucl Med Commun 24:963–970CrossRefPubMed
16.
Zurück zum Zitat Fukunaga H, Sekimoto M, Ikeda M, Higuchi I, Yasui M, Seshimo I, Takayama O, Yamamoto H, Ohue M, Tatsumi M, Hatazawa J, Ikenaga M, Nishimura T, Monden M (2005) Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer. Ann Surg Oncol 12:561–569CrossRefPubMed Fukunaga H, Sekimoto M, Ikeda M, Higuchi I, Yasui M, Seshimo I, Takayama O, Yamamoto H, Ohue M, Tatsumi M, Hatazawa J, Ikenaga M, Nishimura T, Monden M (2005) Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer. Ann Surg Oncol 12:561–569CrossRefPubMed
17.
Zurück zum Zitat Hayashi N, Yamamoto H, Hiraoka N, Dono K, Ito Y, Okami J, Kondo M, Nagano H, Umeshita K, Sakon M, Matsuura N, Nakamori S, Monden M (2001) Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology 34:638–650CrossRefPubMed Hayashi N, Yamamoto H, Hiraoka N, Dono K, Ito Y, Okami J, Kondo M, Nagano H, Umeshita K, Sakon M, Matsuura N, Nakamori S, Monden M (2001) Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology 34:638–650CrossRefPubMed
18.
Zurück zum Zitat Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, Spaulding MB (1998) Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 206:755–760PubMed Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, Spaulding MB (1998) Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 206:755–760PubMed
19.
Zurück zum Zitat Topal B, Flamen P, Aerts R, D'Hoore A, Filez L, Van Cutsem E, Mortelmans L, Penninckx F (2001) Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol 27:175–179CrossRefPubMed Topal B, Flamen P, Aerts R, D'Hoore A, Filez L, Van Cutsem E, Mortelmans L, Penninckx F (2001) Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol 27:175–179CrossRefPubMed
20.
Zurück zum Zitat Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K (2004) Evaluation of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography for gastric cancer. World J Surg 28:247–253CrossRefPubMed Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K (2004) Evaluation of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography for gastric cancer. World J Surg 28:247–253CrossRefPubMed
21.
Zurück zum Zitat Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, Noh SH (2005) Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 103:2383–2390CrossRefPubMed Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, Noh SH (2005) Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 103:2383–2390CrossRefPubMed
22.
Zurück zum Zitat Tian M, Zhang H, Nakasone Y, Mogi K, Endo K (2004) Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging 31:5–12CrossRefPubMed Tian M, Zhang H, Nakasone Y, Mogi K, Endo K (2004) Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging 31:5–12CrossRefPubMed
23.
Zurück zum Zitat Berger KL, Nicholson SA, Dehdashti F, Siegel BA (2000) FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol 174:1005–1008PubMed Berger KL, Nicholson SA, Dehdashti F, Siegel BA (2000) FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol 174:1005–1008PubMed
24.
Zurück zum Zitat Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, Birnbaum EH, Fleshman JW, Kodner IJ, Read TE (2000) Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 43:759–767CrossRefPubMed Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, Birnbaum EH, Fleshman JW, Kodner IJ, Read TE (2000) Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 43:759–767CrossRefPubMed
25.
Zurück zum Zitat Kubota K, Akasu T, Fujita S, Sugihara K, Moriya Y, Yamamoto S (2004) Clinical and pathological prognostic indicators with colorectal mucinous carcinomas. Hepatogastroenterology 51:142–146PubMed Kubota K, Akasu T, Fujita S, Sugihara K, Moriya Y, Yamamoto S (2004) Clinical and pathological prognostic indicators with colorectal mucinous carcinomas. Hepatogastroenterology 51:142–146PubMed
26.
Zurück zum Zitat Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, Tsukada K, Oriuchi N, Inoue T, Endo K (2002) Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94:921–928CrossRefPubMed Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, Tsukada K, Oriuchi N, Inoue T, Endo K (2002) Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94:921–928CrossRefPubMed
27.
Zurück zum Zitat Furudoi A, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F (2001) Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 60:162–169CrossRefPubMed Furudoi A, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F (2001) Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 60:162–169CrossRefPubMed
28.
Zurück zum Zitat Burt BM, Humm JL, Kooby DA, Squire OD, Mastorides S, Larson SM, Fong Y (2001) Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia 3:189–195CrossRefPubMed Burt BM, Humm JL, Kooby DA, Squire OD, Mastorides S, Larson SM, Fong Y (2001) Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia 3:189–195CrossRefPubMed
29.
Zurück zum Zitat Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD (1999) Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 59:4709–4714PubMed Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD (1999) Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 59:4709–4714PubMed
30.
Zurück zum Zitat Burke B, Giannoudis A, Corke KP, Gill D, Wells M, Ziegler-Heitbrock L, Lewis CE (2003) Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 163:1233–1243PubMed Burke B, Giannoudis A, Corke KP, Gill D, Wells M, Ziegler-Heitbrock L, Lewis CE (2003) Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 163:1233–1243PubMed
31.
Zurück zum Zitat Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, Semenza GL (2003) Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1.Cancer Res 63:1138–1143PubMed Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, Semenza GL (2003) Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1.Cancer Res 63:1138–1143PubMed
Metadaten
Titel
Correlation of GLUT-1 Overexpression, Tumor Size, and Depth of Invasion with 18F-2-fluoro-2-deoxy-d-glucose Uptake by Positron Emission Tomography in Colorectal Cancer
verfasst von
Jinyu Gu
Hirofumi Yamamoto
Hiroki Fukunaga
Katsuki Danno
Ichiro Takemasa
Masataka Ikeda
Mitsuaki Tatsumi
Mitsugu Sekimoto
Jun Hatazawa
Tsunehiko Nishimura
Morito Monden
Publikationsdatum
01.12.2006
Erschienen in
Digestive Diseases and Sciences / Ausgabe 12/2006
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9428-2

Weitere Artikel der Ausgabe 12/2006

Digestive Diseases and Sciences 12/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.